Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 19, Issue 6, Pages 273-278

Receiver Operating Characteristic (ROC) to Determine Cut-Off Points of Biomarkers in Lung Cancer Patients

Heidi L. Weiss,1 Santosh Niwas,2 William E. Grizzle,3 and Chandrika Piyathilake4

1Department of Medicine, Baylor College of Medicine, Houston, TX, USA
2Medical Statistics Section, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA
3Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA
4Department of Nutrition Sciences, The University of Alabama at Birmingham, Birmingham, AL, USA

Received 13 July 2004; Accepted 13 July 2004

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The role of biomarkers in disease prognosis continues to be an important investigation in many cancer studies. In order for these biomarkers to have practical application in clinical decision making regarding patient treatment and follow-up, it is common to dichotomize patients into those with low vs. high expression levels. In this study, receiver operating characteristic (ROC) curves, area under the curve (AUC) of the ROC, sensitivity, specificity, as well as likelihood ratios were calculated to determine levels of growth factor biomarkers that best differentiate lung cancer cases versus control subjects. Selected cut-off points for p185erbB-2 and EGFR membrane appear to have good discriminating power to differentiate control tissues versus uninvolved tissues from patients with lung cancer (AUC = 89% and 90%, respectively); while AUC increased to at least 90% for selected cut-off points for p185erbB-2 membrane, EGFR membrane, and FASE when comparing between control versus carcinoma tissues from lung cancer cases. Using data from control subjects compared to patients with lung cancer, we presented a simple and intuitive approach to determine dichotomized levels of biomarkers and validated the value of these biomarkers as surrogate endpoints for cancer outcome.